Barrow Neurological Institute — Biomedical Watch V2

Essais liés23clinical trials

VillePhoenixlocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06106672

Ouvrir le site du centre

Essais cliniques associés

Molécule	Indication / population	Phase	NCT	Titre	Statut
Ocrelizumab	SEP	Phase 4	NCT04377555	Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab	COMPLETED
Prasinezumab	Parkinson	Phase 2	NCT04777331	PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease	ACTIVE_NOT_RECRUITING
Lab Assay for seven genetic variants for Parkinson's Disease	Parkinson	À vérifier	NCT04994015	Parkinson's Foundation PD GENEration Genetic Registry	RECRUITING
Spectris™ AD - Active	Alzheimer	Non applicable	NCT05637801	A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)	COMPLETED
BHV-7000	Épilepsie	Phase 2/3	NCT06132893	RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	RECRUITING
Atogepant	Migraine	Phase 3	NCT03777059	12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine	COMPLETED
Solanezumab	Alzheimer	Phase 3	NCT02008357	A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss	COMPLETED
Neuraceq	Alzheimer	À vérifier	NCT05617014	ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4	ENROLLING_BY_INVITATION
Edaravone (Radicava®/Radicava ORS®)	Sclérose latérale amyotrophique	À vérifier	NCT04259255	Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)	COMPLETED
CNP-106	Myasthénie	Phase 1/2	NCT06106672	Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis	ACTIVE_NOT_RECRUITING
LHP588	Alzheimer	Phase 2	NCT06847321	Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease	RECRUITING
Prasinezumab	Parkinson	Phase 3	NCT07174310	PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease	RECRUITING
ASSESS ALL ALS Study	Sclérose latérale amyotrophique	À vérifier	NCT06578195	ASSESS ALL ALS Study	RECRUITING
PREVENT ALL ALS Study	Sclérose latérale amyotrophique	À vérifier	NCT06581861	PREVENT ALL ALS Study	RECRUITING
COYA 302	Sclérose latérale amyotrophique	Phase 2/3	NCT07161999	ALSTARS — Study of COYA 302 for the Treatment of ALS	RECRUITING
Pridopidine	Sclérose latérale amyotrophique	Phase 3	NCT07322003	PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS	RECRUITING
BIA 28-6156	Parkinson	À vérifier	NCT07522606	Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study	NO_LONGER_AVAILABLE
Ocrelizumab	SEP	Phase 3	NCT05269004	OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis	ACTIVE_NOT_RECRUITING
BIIB100	Sclérose latérale amyotrophique	Phase 1	NCT03945279	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis	COMPLETED
Mexiletine	Sclérose latérale amyotrophique	Phase 2	NCT02781454	Mexiletine in Sporadic Amyotrophic Lateral Sclerosis	COMPLETED
Speech Analysis in ALS Patients	Sclérose latérale amyotrophique	À vérifier	NCT03868345	Speech Analysis in ALS Patients	COMPLETED
Zilucoplan	Sclérose latérale amyotrophique	Phase 2/3	NCT04297683	HEALEY ALS Platform Trial - Master Protocol	ACTIVE_NOT_RECRUITING
CVN424 75 mg	Parkinson	Phase 3	NCT06553027	To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications	ACTIVE_NOT_RECRUITING